View allAll Photos Tagged stemcells
The University of Louisville Division of Cardiovascular Medicine presented the 21st Annual Leonard Leight Lecture on December 10, 2014 in Kornhauser Auditorium on the UofL Health Sciences campus.
The special guest speaker for 2014 was Victor J. Dzau, M.D., President of the Institute of Medicine.
Dr. Dzau presented "Molecular Approaches to Cardiac Regeneration" focusing on understanding cell-based therapy for cardiac regeneration.
Vanessa Campo-Ruiz, Science Officer to the Chief Executive on assignment to the Biomedical Sciences, European Science Foundation
Adam Heathfield, Director Science Policy Europe, Pfizer
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
For more information about our Stem Cell Research Curriculum, please visit www.nwabr.org/curriculum/stem-cell-research
Extracting of my stem cells for my sister
Needle size of your regular fast food drinking straw inserted into my vein.
OUCH!!!!!! D A M N I T! It's hurt like hell!
This is the first screenshot I took in the morning of 9/11 CNN had gone to a slightly simplier home page, but there was still other top stories being listed, including the stem cell issue
The Government of BC is making a major investment in the BC Biotechnology sector, along with Federal and industry partners. A $138 million state-of-the-art regenerative medicine campus in Burnaby will initially create 675 new bio-tech jobs, and up to 2,170 new jobs by 2031. The facility will help establish Canada as a world leader in the area of regenerative medicine.
Vanessa Campo-Ruiz, Science Officer to the Chief Executive on assignment to the Biomedical Sciences, European Science Foundation
Adam Heathfield, Director Science Policy Europe, Pfizer
Magda Chlebus, Director Science Policy, EFPIA
Jonathan Brenton, British Ambassador to Belgium
Duane Schulthess, Commercial Director, Science|Business
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Cell Power No.1
"Lý tưởng hóa tế bào & sạc đầy năng lượng cho tế bào"
Với những ưu điểm vượt trội OHUI Cell Power No.1 đem đến cho người sử dụng cảm giác mát mẻ, mới lạ tuyệt vời nhất.
Thích hợp với tất cả làn da, bất kỳ ai cũng có thể sử dụng được.
Làm da sáng rạng rỡ, cải thiện nếp nhăn và ngăn lão hóa.
Thông minh và có tính ứng dụng cao, giúp khách hàng luôn được sử dụng tinh chất tươi mới nhất.
OHUI Cell Power No.1 cho làn da bừng tỉnh và trẻ trung.
Thành phần:
SCP ( Stemcell power) No 1: tái sinh tế bào mầm. cung cấp năng lượng, dung dịch nuôi dưỡng tế bào mầm trên thân bì & biểu bì.
SCN No 1™: cung cấp dưỡng chất nuôi dưỡng tế bào mầm.
SCV No 1™: tăng cường sức sống cho tế bào mầm. Loại bỏ protein lão hóa, tăng cường sức sống cho tế bào mầm.
Dung tích: 10ml
Giá: 200.000 đ
Call: Mss Thuy - 0943 168 179
The University of Louisville Division of Cardiovascular Medicine presented the 21st Annual Leonard Leight Lecture on December 10, 2014 in Kornhauser Auditorium on the UofL Health Sciences campus.
The special guest speaker for 2014 was Victor J. Dzau, M.D., President of the Institute of Medicine.
Dr. Dzau presented "Molecular Approaches to Cardiac Regeneration" focusing on understanding cell-based therapy for cardiac regeneration.
Amelia Andersdotter, Member, European Parliament
Suchitra Sumitran-Holgersson, Professor of Transplantation Biology, University of Gothenburg
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
The Government of BC is making a major investment in the BC Biotechnology sector, along with Federal and industry partners. A $138 million state-of-the-art regenerative medicine campus in Burnaby will initially create 675 new bio-tech jobs, and up to 2,170 new jobs by 2031. The facility will help establish Canada as a world leader in the area of regenerative medicine.
Stephanie Schissler, Matthew Schissler, Brian Krolicki, Lonnie Hammargren, Somer Hollingsworth - Cord Blood America's Las Vegas, NV Corporate Office and Lab Grand Opening
Senator Chris Dodd and Congressman Chris Murphy (CT-5) joined stem cell researchers, doctors, patient advocates, and Connecticut residents suffering from diseases that may be helped through stem cell research to celebrate President Obama’s recent Executive Order overturning the restrictive stem cell policies put in place by President Bush. Dodd and Murphy were also joined by Cindy Tian, the widow of Dr. Xiangzhong “Jerry” Yang, head of the University of Connecticut’s Center for Regenerative Biology and leading stem cell researcher who passed away last month.
Vanessa Campo-Ruiz, Science Officer to the Chief Executive on assignment to the Biomedical Sciences, European Science Foundation
Adam Heathfield, Director Science Policy Europe, Pfizer
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Vanessa Campo-Ruiz, Science Officer to the Chief Executive on assignment to the Biomedical Sciences, European Science Foundation
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Scanning electron microscope image of newly developed foam biomaterial with just the right amount of random stickiness so that stem cells can adhere and grow into mature tissue cells. Adam Engler, Department of Bioengineering, UC San Diego Jacobs School of Engineering.
Anne M. Petersen, EU consultant, creoDK, Capital Region Denmark EU Office
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Medical conferences bring together a powerful mixture of mature thought leaders and the next generation of experts with the sole goal of designing and completing the advancement in the arena of cancer science & Stem Cell Research that will change the way we do research in cancer science and stem cell field for the better. Medical conferences fill a critical need for pharmaceutical sponsors, providing an unparalleled level of strategic, scientific, and operational expertise in a timely manner.
An International Conference On cancer Science & Stem Cell Research
when-29-30 July, 2019
Where- Amsterdam, Netherlands
Contact : +31728080590
cancerscience@medicalconferences.nl
www.medicalconferences.nl/conference_registration/Cancer-...
Vincent Clay, Manager, EU Government Affairs & Stakeholder Engagement, EU Representation Office, Pfizer
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Motor neuron progenitors (green) derived from human embryonic stem cells. Such neurons could be used to treat spinal cord injuries and diseases of the motor neurons.
This photo was taken by Sharyn Rossi in the lab of Hans Keirstead at the University of California, Irvine.
Learn more about CIRM-funded stem cell research: www.cirm.ca.gov
Shamshad Ahmed of Smart Cells International explains stem cell treatment successes.www.smartcells.com
Paula Salmikangas:
· Senior Researcher. Finnish Medicines Agency. Helsinki, FINLAND
· Vice-Chair of the Committee for Advanced Therapies (CAT), EMA
· Chair of the Cell Products Working Party (CPWP), EMA
I promised Rika we'd visit the Mother&Baby expo, but I was too tired to go on the 17th, so we went on the next day. It was a nice small expo, I bought a stemcell blood preservation in Singapore, we might just need it someday.
Katherine Littler, Policy Adviser, Wellcome Trust
Amelia Andersdotter, Member, European Parliament
Suchitra Sumitran-Holgersson, Professor of Transplantation Biology, University of Gothenburg
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
The Workshop on Treatment of Hematologic Malignancies and Allogeneic Hematopoietic Stem Cell Transplantation using Alternative Donors in September 2012 was a forum for the sharing of new knowledge and the building of bridges between researchers.
Phil Holliday, European Advisor, UK Research Office (UKRO)
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Jessica Cole, Assistant to Vicky Ford, MEP, European Parliament
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Vanessa Campo-Ruiz, Science Officer to the Chief Executive on assignment to the Biomedical Sciences, European Science Foundation
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Wing disc of a fruit fly. The larval wing disc is the source of cells that develop into wings. Fluorescent antibody stain (red) to the nuclear pore, which connects the cytoplasm to the nucleoplasm of the cell. The blue color is a fluorescent stain (DAPI) for DNA in the nucleus.
The staff at Bauman Medical Group is proud to be among the first 100% complete hair transplant teams to become certified in FDA approved Autologel PRP for Hair Restoration Surgery and Wound Healing.
Event : Headshot & Product
Date : 29th March 2015 (13:30 - 18:00)
Location : U Delight @ OnNut Station
Model : Lookkate
Product : Fixx Stemcell Serum
FB : Fixx Stemcell Serum
IG : Fixx Stemcell Serum
Call : 086 0397 8847
Gallery : www.flickr.com/photos/photo_network_group/sets/
Join with Photo Network Group :-